Pharmacoeconomic analysis of various adjunctive pharmacotherapy strategies for back pain using comparative method
https://doi.org/10.21518/2079-701X-2018-6-44-49
Abstract
Spinal disorders are one of the leading causes of disability worldwide. Back pain is one of the most important factors that reduce the patients’ quality of life. The right choice of pharmacotherapy in conjunction with other medical technologies is the key to successful treatment. In addition to drugs that relieve pain, much attention should be paid to the restoration of cartilage in the spine. This paper presents a comparative pharmacoeconomic analysis of the use of chondroitin and glucosamine as the adjunctive therapy.
References
1. Chou R, Côté P, Randhawa K et al. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low-and middle-income communities. Eur Spine J, 2018.
2. Global Burden of Disease 2013 Collaborators (2013) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2013, 386(9995): 743-800.
3. Hogg-Johnson S, van der Velde G, Carroll LJ, Holm LW, Cassidy JD, Guzman J, Côté P, Haldeman S, Ammendolia C, Carragee E, Hurwitz E, Nordin M, Peloso P. The burden and determinants of neck pain in the general population: results of the Bone and Joint Decade 2000– 2010 Task Force on Neck Pain and Its Associated Disorders. Spine, 2008, 33(4 Suppl): 39-51.
4. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epi demio logy of low back pain. Best practice & re search. Clinical rheumatology, 2010 Dec, 24(6): 769-781.
5. Walker BF, Muller R, Grant WD. Low back pain in Australian adults: prevalence and associated disability. J Manipulative Physiol Ther, 2004 May, 27(4): 238-244.
6. Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis, 2014 Jun, 73(6): 968-974.
7. Chronic back pain. Clinical guidelines. Adopted at the 4th Congress of Primary Health Care Professionals of the South of Russia, 9th Conference of General Practitioners (Family Physicians) of the South of Russia, November 7, 2014, Rostov-on-Don. http:// sevgb6.ru/doc/klinicheskie-rekomendacii/xronicheskaya-bol-v-spine.pdf.
8. Levin OS. Efficacy of alflutop in chronic vertebrogenic lumbosciagia based on the results of the double-blind, placebo-controlled study. Nauchno-Prakticheskaya Revmatologiya, 2004, 4: 80-84.
9. Kovalchuk VV. Use of alflutop as an opportunity to increase the efficacy of conventional therapy for patients with back pain. BC, 2014, 10: 777-781.
10. Khodyrev VN, Golikova LG. Clinical efficacy of alflutop in osteochondrosis of the spine (12-month study). Nauchno-Prakticheskaya Revmatologiya, 2004, 5: 33-36.
11. Danilov AB, Zharkova TR, Akhmetzhanova LT. Analgesic effects of Alflutop therapy for chronic back pain. Consilium Medicum. Nevrologiya i Revmatologiya. (Appendix), 2010, 2: 26-29.
Review
For citations:
Balunov PA. Pharmacoeconomic analysis of various adjunctive pharmacotherapy strategies for back pain using comparative method. Meditsinskiy sovet = Medical Council. 2018;(6):44-49. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-44-49
Views:
599
Email this article 